X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1251) 1251
Publication (124) 124
Newsletter (43) 43
Book Review (19) 19
Book Chapter (14) 14
Newspaper Article (11) 11
Magazine Article (6) 6
Conference Proceeding (3) 3
Dissertation (2) 2
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pazopanib (1286) 1286
index medicus (691) 691
oncology (610) 610
humans (589) 589
sunitinib (446) 446
cancer (369) 369
female (334) 334
male (322) 322
metastasis (264) 264
middle aged (262) 262
sorafenib (261) 261
aged (243) 243
care and treatment (238) 238
renal cell carcinoma (225) 225
carcinoma, renal cell - drug therapy (213) 213
adult (203) 203
carcinoma, renal cell (200) 200
kidney neoplasms - drug therapy (197) 197
research (189) 189
drug therapy (187) 187
survival (185) 185
pyrimidines - therapeutic use (184) 184
sulfonamides - therapeutic use (181) 181
chemotherapy (178) 178
interferon-alpha (171) 171
treatment outcome (171) 171
bevacizumab (170) 170
sarcoma (169) 169
antineoplastic agents - therapeutic use (161) 161
pharmacology & pharmacy (157) 157
vascular endothelial growth factor (156) 156
double-blind (150) 150
trial (144) 144
angiogenesis (143) 143
tumors (140) 140
analysis (134) 134
everolimus (133) 133
kidney neoplasms - pathology (132) 132
therapy (132) 132
disease-free survival (126) 126
kidney cancer (126) 126
angiogenesis inhibitors - therapeutic use (124) 124
patients (124) 124
medicine & public health (122) 122
pyrimidines - adverse effects (117) 117
sulfonamides - adverse effects (116) 116
urology & nephrology (116) 116
axitinib (114) 114
dosage and administration (113) 113
endothelial growth-factor (112) 112
tyrosine kinase inhibitor (111) 111
efficacy (110) 110
targeted therapy (110) 110
angiogenesis inhibitors (109) 109
aged, 80 and over (107) 107
clinical trials (107) 107
prognosis (106) 106
renal-cell carcinoma (104) 104
health aspects (103) 103
tyrosine (103) 103
pyrimidines - administration & dosage (100) 100
sulfonamides - administration & dosage (99) 99
tyrosine kinase inhibitors (95) 95
carcinoma, renal cell - pathology (93) 93
patient outcomes (92) 92
hematology, oncology and palliative medicine (86) 86
protein kinase inhibitors - therapeutic use (86) 86
phase-ii (85) 85
cancer therapies (83) 83
antineoplastic agents (81) 81
antineoplastic agents - adverse effects (80) 80
retrospective studies (80) 80
soft tissue sarcoma (80) 80
soft-tissue sarcoma (80) 80
animals (79) 79
metastases (79) 79
carcinoma (78) 78
open-label (77) 77
antimitotic agents (76) 76
development and progression (75) 75
angiogenesis inhibitors - adverse effects (73) 73
antineoplastic combined chemotherapy protocols - therapeutic use (72) 72
vegf (72) 72
complications and side effects (71) 71
pyrimidines - pharmacology (71) 71
young adult (71) 71
neoplasms. tumors. oncology. including cancer and carcinogens (70) 70
article (69) 69
immunotherapy (69) 69
neoplasm metastasis (67) 67
safety (67) 67
hypertension (66) 66
sulfonamides - pharmacology (65) 65
inhibitor (64) 64
expression (63) 63
sarcoma - drug therapy (63) 63
case report (61) 61
carcinoma, renal cell - secondary (60) 60
medical research (59) 59
molecular targeted therapy (59) 59
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1249) 1249
German (29) 29
French (21) 21
Russian (9) 9
Korean (7) 7
Hungarian (2) 2
Polish (2) 2
Spanish (2) 2
Czech (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. e20649 - e20649
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 05/2019, Volume 17, Issue 5, pp. 625 - 628
The past year has led to significant changes in systemic therapies used to treat soft tissue sarcomas, mainly dominated by the removal of the recently approved... 
PAZOPANIB | ONCOLOGY
Journal Article
11/2013
Low Dose Metronomic (LDM) chemotherapy, combined with VEGF pathway inhibitors, is a highly effective strategy to coordinately inhibit angiogenesis and tumor... 
Angiogenesis | Pediatric cancer | 0992 | Metronomic topotecan | Pazopanib
Dissertation
Internal Medicine, ISSN 0918-2918, 2018
The clinical efficacy and outcomes of pazopanib treatment for metastatic extraosseous Ewing sarcoma remain unclear. We herein report a case of heavily... 
extraosseous Ewing sarcoma | pazopanib
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 07/2016, Volume 142, Issue 1, pp. 89 - 94
Background Uterine sarcomas are a group of mesenchymal tumours comprising several histologies. They have a high recurrence rate following surgery, modest... 
Soft tissue sarcoma | Uterine sarcoma | Pazopanib
Journal Article
The Korean Journal of Internal Medicine, ISSN 1226-3303, 2018, Volume 33, Issue 2, p. 442
Journal Article
Journal of Gynecologic Oncology (JGO), ISSN 2005-0380, 2018, Volume 29, Issue 1, p. 1
Objective: In the treatment of metastatic soft tissue sarcoma (STS), pazopanib is considered a standard treatment after failure of chemotherapy. We... 
Sarcoma; Uterus; Endometrium; Pazopanib
Journal Article
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 8/2017, Volume 23, Issue 15, pp. 4027 - 4034
Journal Article
Annals of Oncology, ISSN 0923-7534, 02/2019, Volume 30, Issue 2, pp. 317 - 324
Abstract Background Advanced melanoma treatments often rely on immunotherapy or targeting mutations, with few treatment options for wild-type BRAF (BRAF-wt)... 
Phase II | Pazopanib | Trametinib | Braf wild-type | Melanoma | trametinib | SURVIVAL | phase II | NRAS | MEK INHIBITION | ONCOLOGY | melanoma | SELUMETINIB | BRAF wild-type | pazopanib | DOCETAXEL | CANCER | Index Medicus | Original
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 06/2019, Volume 25, Issue 12, pp. 3486 - 3494
Purpose: No antiangiogenic treatment is yet approved for extrapancreatic neuroendocrine tumors (NET). Surufatinib (HMPL-012, previously named sulfatinib) is a... 
DIAGNOSIS | EVEROLIMUS | PAZOPANIB | ONCOLOGY | BEVACIZUMAB | SUNITINIB | DEPOT OCTREOTIDE | INHIBITOR
Journal Article
The Oncologist, ISSN 1083-7159, 01/2018, Volume 23, Issue 1, pp. 62 - 70
Background Alveolar soft part sarcoma (ASPS) is an exceedingly rare and orphan disease, without active drugs approved in the front line. Pazopanib and... 
Chemotherapy | Sarcoma | Trabectedin | Alveolar soft part sarcoma | Pazopanib | SOLID TUMORS | EFFICACY | TISSUE SARCOMA | PHASE-II | ANTITUMOR-ACTIVITY | METASTATIC LIPOSARCOMA | ONCOLOGY | SUNITINIB | MUSCULOSKELETAL ONCOLOGY GROUP | TUMOR MICROENVIRONMENT | Sarcomas
Journal Article
Journal of Pediatric Hematology/Oncology, ISSN 1077-4114, 2018, p. 1
Axial skeleton primary tumor, metastatic disease at presentation, incomplete surgical resection, and <90% tumor necrosis have all been known to influence... 
relapsed | pediatric osteosarcoma | pazopanib | MAP | oncology
Journal Article
The Journal of Dermatology, ISSN 0385-2407, 07/2019, Volume 46, Issue 7, pp. e263 - e265
Journal Article
Gan to kagaku ryoho. Cancer & chemotherapy, ISSN 0385-0684, 06/2016, Volume 43, Issue 6, pp. 785 - 787
Journal Article
Bulletin du Cancer, ISSN 0007-4551, 09/2017, Volume 104, Issue 9, pp. 705 - 706
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 11/2014, Volume 32, Issue 33
Journal Article
ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 12/2014, Volume 37, Issue 12, pp. 795 - 795
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 07/2015, Volume 33, Issue 21, pp. 2384 - U88
Purpose On the basis of evidence that resistance to vascular endothelial growth factor (VEGF) receptor inhibition is caused by hypoxia-driven residual VEGF and... 
BIOMARKERS | SURVIVAL | INTERFERON-ALPHA | PAZOPANIB | EVEROLIMUS | EFFICACY | ONCOLOGY | DOUBLE-BLIND | SUNITINIB | TOXICITY
Journal Article
British Journal of Cancer, ISSN 0007-0920, 11/2014, Volume 111, Issue 10, pp. 1909 - 1916
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.